General Information of Drug (ID: DMHU742)

Drug Name
EPZ032597 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Preclinical [1]
Cross-matching ID
PubChem CID
132220034
TTD Drug ID
DMHU742

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AZ505 DMKQ20J Solid tumour/cancer 2A00-2F9Z Preclinical [2]
LLY-507 DMNOE1M Solid tumour/cancer 2A00-2F9Z Preclinical [3]
EPZ033294 DMDO6NZ Solid tumour/cancer 2A00-2F9Z Preclinical [1]
A-893 DM8XHJG Lung cancer 2C25.0 Preclinical [4]
BAY 598 DMWH19X Discovery agent N.A. Preclinical [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
SET and MYND domain-containing protein 2 (SMYD2) TT7YJFO SMYD2_HUMAN Inhibitor [1]

References

1 Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
2 Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011 Sep 7;19(9):1262-73.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2714).
4 Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. ACS Med Chem Lett. 2015 Apr 29;6(6):695-700.
5 Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2. J Med Chem. 2016 May 26;59(10):4578-600.